OWEN KATEY EINTERZ sold $250K of ADPT

OWEN KATEY EINTERZ sold 9,615 shares of Adaptive Biotechnologies Corp (ADPT) at $26.00 ($0.25M total) on 2026-08-26.

Original reporting
SEC EDGAR · OWEN KATEY EINTERZ
Published Aug 28, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The director's sale adds modest negative pressure, but the overall impact on ADPT's valuation is limited.

02

Market read

Primary insider sale provides new information for short‑term traders; limited long‑term effect.

03

What to watch

Einterz's remaining 78,639 shares still represent a sizable stake, mitigating concern.

Relevance 4/10Novelty 4/10Timing: post‑market Aug 26, filed Aug 28

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

Director Owen Katey Einterz sold 9,615 shares of Adaptive Biotechnologies for $250K on Aug 26, 2026.

Expected impact

Potential short-term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Director sales often weigh on investor perception; however, the $250K amount is small for a mid‑cap biotech.

Market effects

Minor negative signal for biotech sector insiders, but unlikely to affect broader sector.

No significant regional effect; confined to US biotech investors.

Limited global relevance; only impacts ADPT shareholders.

Counterpoint

The sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Adaptive Biotechnologies Corp

    US‑listed biotech (ticker ADPT) focused on immune profiling.

  • Owen Katey Einterz

    Director of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.